case_images: PMC7445493_01
case_images: Image study and therapeutic evaluation. (A) CT scan showed primary lung lesion in right middle lobe and metastasis to subcarinal lymph node, ipsilateral lung and left eighth rib in baseline; (B) PR assessment during crizotinib because of the shrinking of lung lesions and elimination of lymph node; (C) progression when resistant to crizotinib (hydrothorax and subcutaneous metastasis) and the partial response (PR) to ceritinib in hydrothorax elimination and subcutaneous lesion control.
case_images: OTT-13-8313-g0001.jpg
case_images: PMC7445493_01_OTT-13-8313-g0001.jpg
case_images: f0001
case_images: Lesions in the ipsilateral superior lobe and left eighth rib were considered to be metastatic (Figure 1A). According to the Response Evaluation Criteria in Solid Tumors version 1.1, the patient was evaluated after 2 months of treatment and found to have achieved a partial response (PR), as evidenced by shrinkage of the lung lesions and elimination of lymph-node lesions (Figure 1B). PFS, with the best evaluation of PR (Figure 1C). Progression occurred in the lung, and subcutaneous lesions with the recurrence of hydrothorax were observed later.